Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD
| Autor: | Nicholas T. Kruse |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Physiology Anti-Inflammatory Agents Awards and Prizes Inflammation Review Disease 030204 cardiovascular system & hematology Nitric Oxide medicine.disease_cause Antioxidants 03 medical and health sciences 0302 clinical medicine Nutraceutical Risk Factors Physiology (medical) medicine Animals Humans Vascular Diseases Renal Insufficiency Chronic Risk factor Intensive care medicine business.industry Public health Hemodynamics Prognosis medicine.disease Adjunct Oxidative Stress Treatment Outcome 030104 developmental biology Dietary Supplements Inflammation Mediators medicine.symptom business Oxidative stress Signal Transduction Kidney disease |
| Zdroj: | Am J Physiol Regul Integr Comp Physiol |
| ISSN: | 1522-1490 0363-6119 |
| DOI: | 10.1152/ajpregu.00152.2019 |
| Popis: | Chronic kidney disease (CKD) is a major public health epidemic and increases risk for developing cardiovascular disease (CVD). Vascular dysfunction is a major independent risk factor toward increased risk for CVD in CKD. Several mechanisms have been postulated to result in vascular dysfunction in CKD, including oxidative stress-mediated inflammation by redox imbalance and reduced nitric oxide (NO) bioavailability and synthesis. Therefore, strategies that decrease oxidative stress and/or increase NO bioactivity may have major clinical implications toward improving vascular health and reducing the burden of CVD in CKD. Nutraceutical therapy in the form of polyphenols, dietary nitrates, or selective mitochondria-targeting therapies has recently been shown to improve vascular function by reducing oxidative stress and/or increasing NO bioavailability and synthesis. This review, therefore, highlights these three emerging nutraceuticals recently implicated in pathophysiological improvement of vascular function in CKD. This review also describes those pathophysiological mechanisms thought to be responsible for the beneficial effects on the vasculature and possible experimental considerations that may exist within human CKD populations. It is clear throughout this review that human-based mechanistic preclinical and health-related clinical studies are lacking regarding whether nutraceuticals do indeed improve vascular function in patients with CKD. As such, a comprehensive, detailed, and fully integrated understanding of nutraceuticals and vasculature function is necessary in patients with CKD. Many opportunities exist for original mechanistic and therapeutic discoveries and investigations on select nutraceuticals and their impact on vascular outcomes in patients with CKD, and these will remain exciting avenues of research in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|